老年脑梗死并发尿道感染患者病原菌分布及耐药性分析

目的:分析老年脑梗死并发尿道感染的病原菌分布及其耐药性。方法:选取2014年9月-2016年9月于我院治疗的240例老年脑梗死并发尿道感染患者为研究对象,收集患者中段尿标本进行细菌分离培养鉴定,分析病原菌分布情况并测定其耐药性。结果:共检出160株病原菌,其中革兰阴性菌108株,占67.50%,革兰阳性菌43株,占26.88%,真菌9株,占5.63%,前五位病原菌分别为大肠埃希菌、铜绿假单胞菌、肺炎克雷伯菌、溶血性葡萄球菌及粪肠球菌。在主要革兰阴性菌中,大肠埃希菌对头孢曲松耐药率最高(69.81%),对亚胺培南最敏感(3.77%);铜绿假单胞菌对环氧沙星耐药率最高(88.24%),对头孢曲松、头孢唑啉、头孢他啶、阿米卡星、哌拉西林、亚胺培南最敏感,耐药率均为0.00%;肺炎克雷伯菌对头孢唑林耐药率最高(75.00%),对呋喃妥因最敏感(6.25%)。在主要革兰阳性菌中,金黄色葡萄球菌对红霉素耐药率最高(85.71%);肠球菌属(粪肠球菌及屎肠球菌)对氨苄西林耐药率最高(70.00%);凝固酶阴性葡萄球菌(溶血性葡萄球菌及表皮葡萄球菌)对头孢曲松耐药率最高(93.75%);主要革兰阳性菌对万古霉素、利奈唑胺最敏感,耐药率均为0.00%。结论:老年脑梗死并发尿道感染病原菌种类多,应根据耐药性结果合理选用抗生素。     

老年女性泌尿系统感染患者的病原菌分布及耐药情况研究

目的通过对老年女性泌尿系统感染患者病原菌类型和耐药情况进行研究,为临床合理、安全、有效使用抗菌药物提供依据。方法收集2014年9月至2017年7月在我院进行诊治的661例老年女性泌尿系统感染患者,对其清晨清洁中段尿进行细菌培养并进行耐药试验。结果 661例样本中共分离出病原菌255株,其中革兰阴性菌165株,占64.7%,以大肠埃希菌为主,构成比为45.5%;革兰阳性菌77株,占30.2%,以屎肠球菌为主,构成比为10.2%;真菌13株,占5.1%。G-菌中检出率排在前三的依次是大肠埃希菌、肺炎克雷伯菌、奇异变形杆菌。大肠埃希菌、肺炎克雷伯菌对氨苄西林、复方新诺明耐药性较高,奇异变形杆菌对头孢唑啉耐药性较高,三者均对亚胺培南敏感性较高。G+菌中检出率排在前三的依次是屎肠球菌、表皮葡萄球菌、粪肠球菌。三种病原菌对青霉素、氨苄西林、环丙沙星耐药性较高,对万古霉素、替考拉宁敏感性较高。结论老年女性泌尿系统感染患者的病原菌多数为革兰阴性菌,且以大肠埃希菌为主,病原菌培养和耐药试验对于临床合理有效地使用抗菌药物具有重要的指导意义。     

医院血培养的病原菌分布及耐药性分析

目的 了解我院2006年至2008年血培养中病原菌的阳性率、分布及其对药物的敏感情况,为临床治疗菌血症提供用药依据.方法 采用自动血培养仪对血培养瓶进行连续培养监测,全自动微生物分析系统对血标本中分离的病原菌进行鉴定和药物敏感试验.结果 1002份血培养标本分离出病原菌103株,阳性率10.3%,其中革兰阴性菌58株,占56.3%;革兰阳性菌32株,占31.9%;真菌10株,占9.7%.革兰阴性菌中,大肠埃希菌、肺炎克雷伯菌对氨苄西林的耐药率最高,分别为92.7%和92.3%.革兰阳性菌中,金黄色葡萄球菌、凝固酶阴性葡萄球菌对青霉素耐药率达100%,肠球菌对常用抗生素呈高度耐药,未发现葡萄球菌对万古霉素耐药,但有9.1%的肠球菌对万古霉素呈中介.结论 目前我院血培养分离的病原菌分布较广,大肠埃希菌和葡萄球菌是菌血症和(或)败血症的主要病原菌;药敏结果提示检出菌耐药性严重且广谱耐药,及时准确的血培养结果能为临床合理选择抗菌药物提供重要依据.     

前列腺增生患者术后并发尿路感染的病原菌分布、耐药性和危险因素分析

目的:探讨前列腺增生患者术后并发尿路感染的病原菌分布、耐药性和危险因素。方法:回顾性分析2014年6月到2018年10月期间成都医学院第一附属医院行手术治疗的323例前列腺增生患者的临床资料,采用单因素和多因素Logistic回归分析方法分析前列腺增生患者术后并发尿路感染的危险因素。收集所有患者术后12h内的中段尿样,进行病原菌检测和耐药性分析。结果:323例前列腺增生患者共有50例术后并发尿路感染,发生率为15.48%,50例术后并发尿路感染患者的尿液标本中共分离出53株病原菌,其中革兰阳性菌23株,占43.40%,革兰阴性菌27株,占50.94%,真菌3株,占5.66%。屎肠球菌对青霉素、红霉素耐药性较高,粪肠球菌对青霉素、红霉素、氨苄西林耐药性较高,屎肠球菌和粪肠球菌对万古霉素、呋喃妥因的耐药性较低。大肠埃希菌对氨曲南、氨苄西林、左氧氟沙星耐药性较高,铜绿假单胞菌对氨曲南、氨苄西林耐药性较高,大肠埃希菌和铜绿假单胞菌对亚胺培南的耐药性较低。经单因素分析显示,前列腺增生患者术后并发尿路感染与年龄、前列腺体积、手术时间、术后留置尿管时间、是否合并糖尿病、术前是否预防性应用抗生素有关(P0.05),多因素Logistic回归分析结果显示,年龄≧65岁、手术时间≧60 min、术后留置尿管时间≧7d、合并糖尿病、术前未预防性应用抗生素均是前列腺增生患者术后并发尿路感染的危险因素(P0.05)。结论:前列腺增生患者术后易出现尿路感染,感染病原菌以革兰阴性菌和革兰阳性菌为主,临床应根据尿路感染的危险因素和药敏实验结果而采取针对性的防治措施。     

医院血流感染病原菌分布及耐药性分析

目的了解医院血流感染病原菌的分布及其耐药性,为临床治疗提供参考。方法收集2013年1月至12月浙江中医药大学附属第一医院患者血培养标本,采用WHONET 5.6软件对所分离的病原菌及药敏结果进行统计分析。结果 2 017份血培养标本共检出病原菌370株,阳性率为18.34%,其中革兰阳性菌142株占38.38%,革兰阴性菌213株占57.57%,真菌15株,占4.05%。排名前5位病原菌依次是凝固酶阴性葡萄球菌、大肠埃希菌、肺炎克雷伯菌、肠球菌属和金黄色葡萄球菌,分别占19.73%、17.03%、13.51%、6.22%和4.59%。除哌拉西林/他唑巴坦对大肠埃希菌和铜绿假单胞菌仍保持较高的抗菌活性外,革兰阴性菌尤其是肺炎克雷伯菌对多种药物均产生了严重耐药性,其中产ESBLs大肠埃希菌和肺炎克雷伯菌分别占46.80%和20.00%。革兰阳性菌对利奈唑胺100%敏感,检出耐甲氧西林金黄色葡萄球菌(MRSA)4株,占25.00%,耐甲氧西林凝固酶阴性葡萄球菌(MRCNs)占92.00%,耐万古霉素的表皮葡萄球菌1株和耐万古霉素的粪肠球菌3株。结论血流感染病原菌分布复杂,以革兰阴性菌为主,耐药率高,且已出现耐万古霉素的表皮葡萄球菌和粪肠球菌,因此,进行早期监测和耐药性分析非常必要,对控制感染、指导合理使用抗菌药物,减缓耐药菌株的出现具有重要的临床意义。     

舟山地区2688例胆汁培养病原菌分布及耐药性分析

目的通过分析2007年到2010年舟山医院2 688例胆汁标本中病原菌的分布及耐药状况,为临床合理用药提供实验依据。方法对2 688例胆汁标本进行细菌培养、鉴定和药敏分析。结果 2 688例胆汁标本中共检出阳性标本611例(阳性率22.7%),其中革兰阴性菌占82.2%(502/611),革兰阳性菌占13.3%(81/611),真菌占4.6%(28/611)。主要的病原菌为大肠埃希菌(40.3%)、肺炎克雷伯菌(15.4%)、肠球菌(11.3%);阴沟肠杆菌(4.7%)等。大肠埃希菌和肺炎克雷伯菌的ESBLs阳性菌株的比例达到了21.0%和5.9%,其中ESBLs阴性菌株对头孢他啶、头孢吡肟、美罗培南和阿米卡星等药物较为敏感,而ESBLs阳性菌株只对美罗培南和亚胺培南敏感;革兰阳性菌对万古霉素、氨苄西林较敏感。结论舟山地区胆道感染以革兰阴性菌为主,大肠埃希菌产ESBLs的菌株有较高的比例,临床应加强对抗生素的合理使用。     

2008年至2010年泌尿系统感染中病原菌的分布及耐药性分析

目的了解泌尿系统感染的病原菌分布及药物耐药性。方法采用法国生物梅里埃公司的VITEK60分析仪对2008年至2010年宁波市妇女儿童医院疑为泌尿系统感染患者的尿液标本进行细菌培养、菌株鉴定,纸片扩散确证试验检测ESBLs。结果 2008年至2010年尿标本中共分离出病原菌1 561株,以大肠埃希菌最多见,占27.2%,其次肺炎克雷伯菌、奇异变形菌、粪肠球菌(D群),各占6.34%、6.28%和6.21%,再次是表皮葡萄球、白色念珠菌和屎肠球菌(D群),各占4.48%、4.36%和3.91%。表皮葡萄球、粪肠球菌(D群)、屎肠球菌(D群)对万古霉素均敏感,对利奈唑烷仅1株粪肠球菌(D群)耐药。3年中,无1例大肠埃希菌对亚胺培南耐药,1株肺炎克雷伯菌和1株奇异变形菌对亚胺培南耐药,其他药物均有不同程度耐药。结论大肠埃希菌是导致泌尿系统感染最常见的致病菌,产ESBLs的菌株已达46.6%。治疗由产ESBLs细菌引起的尿路感染首选亚胺培南和哌拉西林/他唑巴坦;引起尿路感染的革兰阳性菌主要为肠球菌,青霉素可作为治疗粪肠球菌引起的尿路感染,但不适合治疗屎肠球菌引起的尿路感染,耐药率已达95%以上,呋喃妥因、利奈坐烷、万古霉素可作为首选。     

125例胆道疾病患者胆汁细菌培养及药敏鉴定分析

目的分析胆道手术患者胆汁中病原菌的分布及耐药情况,以指导临床合理选择抗菌药物。方法回顾分析2012年6月至2014年6月两家医院125例胆汁细菌培养阳性病原菌的菌种分布及药敏鉴定结果。结果 125株病原菌中,革兰阴性菌77株(占61.6%),革兰阳性菌42株(占33.6%),真菌6株(占4.8%)。胆汁中的主要致病菌依次为大肠埃希菌、肠球菌属、克雷伯菌属、假单胞菌属和葡萄球菌属。药敏试验显示,革兰阴性菌中耐药率最低的是碳青霉烯类,耐药率较高的是氨苄西林(82.4%)、头孢唑啉(69.4%)、氨苄西林/舒巴坦(68.4%);革兰阳性菌对替加环素、利奈唑烷的耐药率为0.0%,而对克林霉素(76.1%)、红霉素(58.3%)、青霉素G(56.4%)的耐药率较高。结论两家医院胆道感染仍以革兰阴性菌为主,肠球菌属感染率呈上升趋势。胆汁中病原菌感染率较高及分布广泛,且对抗生素的耐药性较高,重视胆汁细菌培养及鉴定有助于临床合理选择抗菌药物。     

呼吸内科下呼吸道感染病原菌分布及耐药性分析

目的探讨和分析下呼吸道感染患者的病原菌分布及其耐药性。方法回顾性分析2013年在金华市中心医院呼吸内科住院的下呼吸道感染患者合格痰标本细菌培养结果,然后进行细菌菌株的鉴定和药物敏感性检测。结果共分离出593株致病菌。其中,革兰阴性菌464株,占78.2%,前四位为:肺炎克雷伯菌、铜绿假单胞菌、鲍曼不动杆菌、大肠埃希菌;革兰阳性菌49株(占8.3%),以金黄色葡萄球菌为主;真菌80株(占13.5%),以白假丝酵母菌为主。不论是革兰阴性杆菌还是革兰阳性球菌均普遍出现了多重耐药菌株。结论呼吸内科下呼吸道感染以革兰阴性菌为主,分离病原菌耐药现象普遍存在,临床应重视病原学检查。加强病原菌耐药性监测,合理使用抗菌药物。     

407例老年肺癌下呼吸道感染患者病原菌分布及耐药分析

目的 分析老年肺癌下呼吸道感染患者痰培养物的病原菌分布及耐药状况.方法 回顾性分析407例老年肺癌下呼吸道感染患者痰标本细菌培养、鉴定及药敏结果.结果 共分离出病原菌238株,革兰阴性菌163株,占68.49％;革兰阳性菌33株,占13.87％;真菌42株,占17.65％.主要病原菌为肺炎克雷伯菌、大肠埃希菌、铜绿假单胞菌、鲍曼不动杆菌、表皮葡萄球菌和金黄色葡萄球菌.其中,肺炎克雷伯菌和大肠埃希菌ESBLs阳性菌株的比例分别为36.73％、28.85％.结论 老年肺癌患者因长期使用抗生素,呼吸道菌群失调,不同病原菌对抗菌药耐药率均较高,以革兰阴性菌感染为主,肺炎克雷伯菌和大肠埃希菌产ESBLs的菌株有较高比例,二重感染比例较高;革兰阳性菌均对万古霉素敏感,未发现耐药菌株.因此临床医生根据药敏结果合理选用抗生素,对于改善患者肺部微生态失衡,延长生存时间具有重要指导意义.     

Recent advances in the study of Kaposi's sarcoma-associated herpesvirus replication and pathogenesis

It has now been over twenty years since a novel herpesviral genome was identified in Kaposi's sarcoma biopsies. Since then, the cumulative research effort by molecular biologists, virologists, clinicians, and epidemiologists alike has led to the extensive characterization of this tumor virus, Kaposi's sarcoma-associated herpesvirus(KSHV; also known as human herpesvirus 8(HHV-8)), and its associated diseases. Here we review the current knowledge of KSHV biology and pathogenesis, with a particular emphasis on new and exciting advances in the field of epigenetics. We also discuss the development and practicality of various cell culture and animal model systems to study KSHV replication and pathogenesis.     

A Unique Protease Cleavage Site Predicted in the Spike Protein of the Novel Pneumonia Coronavirus (2019-nCoV) Potentially Related to Viral Transmissibility

正Dear Editor,In December 2019, a novel human coronavirus caused an epidemic of severe pneumonia(Coronavirus Disease 2019,COVID-19) in Wuhan, Hubei, China(Wu et al. 2020; Zhu et al. 2020). So far, this virus has spread to all areas of China and even to other countries. The epidemic has caused 67,102 confirmed infections with 1526 fatal cases     

Curcuminoids as inhibitors of thioredoxin reductase: A receptor based pharmacophore study with distance mapping of the active site

Curcumin is the yellow pigment of turmeric that interacts irreversibly forming an adduct with thioredoxin reductase (TrxR), an enzyme responsible for redox control of cell and defence against oxidative stress. Docking at both the active sites of TrxR was performed to compare the potency of three naturally occurring curcuminoids, namely curcumin, demethoxy curcumin and bis-demethoxy curcumin. Results show that active sites of TrxR occur at the junction of E and F chains. Volume and area of both cavities is predicted. It has been concluded by distance mapping of the most active conformations that Se atom of catalytic residue SeCYS498, is at a distance of 3.56 from C13 of demethoxy curcumin at the E chain active site, whereas C13 carbon atom forms adduct with Se atom of SeCys 498. We report that at least one methoxy group in curcuminoids is necessary for interation with catalytic residues of thioredoxin. Pharmacophore of both active sites of the TrxR receptor for curcumin and demethoxy curcumin molecules has been drawn and proposed for design and synthesis of most probable potent antiproliferative synthetic drugs.     

Comparative morphology of the carpel in the Liliaceae: Hewardieae, Petrosavieae, and Tricyrteae

The young pistils in the melanthioid tribes, Hewardieae, Petrosavieae and Tricyrteae, are uniformly tricarpellate and syncarpous. They lack raphide idioblasts. All are multiovulate, with bitegmic ovules. The Petrosavieae are marked by the presence of septal glands and incomplete syncarpy. Tepals and stamens adhere to the ovary in the Hewardieae and the Petrosavieae but not in the Tricyrteae. Two vascular bundles occur in the stamens of the Hewartlieae and Tricyrtis latifolia. Ventral bundles in the upper part of the ovary of the Hewardieae are continuous with compound septal bundles and placental bundles in the lower part. Putative ventral bundles occur in the alternate position in the Tricyrteae and putative placental bundles in the opposite. position in the Petrosavieae. The dichtomously branched stigma in each carpel of the Tricyrteae is supplied by a bifurcated dorsal bundle.     

Synthesis and antimicrobial studies of hydrazone derivatives of 4-[3-(2,4-difluorophenyl)-4-formyl-1H-pyrazol-1-yl]benzoic acid and 4-[3-(3,4-difluorophenyl)-4-formyl-1H-pyrazol-1-yl]benzoic acid

Microbial resistance to antibiotics is an unresolved global concern, which needs urgent and coordinated action. One of the guidelines of the Centers for Disease Control and Preventions (CDC) to combat antibiotic resistance is the development of new antibiotics to treat drug-resistant bacteria. In our effort to find new antibiotics, we report the synthesis and antimicrobial studies of 30 new pyrazole derivatives. These novel molecules have been synthesized by using readily available starting materials and benign reaction conditions. Some of these molecules have shown activity with MIC values as low as 0.78?µg/mL against four bacterial strains; Staphylococcus aureus, methicillin-resistant S. aureus, Bacillus subtilis, and Acinetobacter baumannii. Furthermore, active molecules are non-toxic to mammalian cell line.

     

Novel compounds with potent CDK9 inhibitory activity for the treatment of myeloma

Cyclin-dependent kinases (CDKs) and Polo-like kinases (PLKs) play key role in the regulation of the cell cycle. The aim of our study was originally the further development of our recently discovered polo-like kinase 1 (PLK1) inhibitors. A series of new 2,4-disubstituted pyrimidine derivatives were synthesized around the original hit, but their PLK1 inhibitory activity was very poor. However the novel compounds showed nanomolar CDK9 inhibitory activity and very good antiproliferative effect on multiple myeloma cell lines (RPMI-8226).